Reduced antioxidant capacities in platelets from patients with autoimmune thrombocytopenia purpura (ITP)

Platelets

Volumn 23, Issue 3, 2012, Pages 184-194

  Kamhieh Milz, Julian ^a   Bal, Grkan ^a   Sterzer, Viktor ^a   Kamhieh Milz, Sundrela ^a   Arbach, Olga ^a   Salama, Abdulgabar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antioxidant enzymes; Autoimmune thrombocytopenia; ITP; Oxidative stress; Total antioxidant capacity

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CATALASE; DEXAMETHASONE; FIBRINOGEN RECEPTOR; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; IMMUNOGLOBULIN; PREDNISOLONE;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; BIOAVAILABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME ACTIVITY; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; REMISSION; SPLENECTOMY; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE RICH PLASMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIOXIDANTS; BLOOD PLATELETS; FEMALE; FLUORESCEINS; HEMORRHAGE; HUMANS; HYDROGEN PEROXIDE; MALE; MIDDLE AGED; OXIDATIVE STRESS; OXIDOREDUCTASES; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 84859735884     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2011.610909     Document Type: Article

References (57)

1. Semple JW, Freedman J. Platelets and innate immunity. Cell Mol Life Sci 2010;67:499-511.
2. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003;23:2131-2137.
3. Aukrust P, Halvorsen B, Ueland T, Michelsen AE, Skjelland M, Gullestad L, Yndestad A, Otterdal K. Activated platelets and atherosclerosis. Expert Rev Cardiovasc Ther 2010;8:1297-1307.
4. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011;11:123-134.
5. Ahmed SM, O'Leary EL, Innone LA. Antiplatelet therapy in cardiovascular disease. Compr Ther 2010;36:20-22.
6. Sowa JM, Crist SA, Ratliff TL, Elzey BD. Platelet influence on T- and B-cell responses. Arch Immunol Ther Exp (Warsz) 2009;57:235-241.
7. Coopamah MD, Garvey MB, Freedman J, Semple JW. Cellular immune mechanisms in autoimmune thrombocytopenic purpura: An update. Transfus Med Rev 2003;17:69-80.
8. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: Pathogenic and clinical diversity. Blood 2009;113:6511-6521.
9. Salama A. Modified treatment options for primary immune thrombocytopenia (ITP). Expert Rev Hematol 2011;4(1).
10. McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol 2000;37:239-248.
11. Kuwana M, Ikeda Y. The role of autoreactive T-cells in the pathogenesis of idiopathic thrombocytopenic purpura. Int J Hematol 2005;81:106-112.
12. Gernsheimer T. Chronic idiopathic thrombocytopenic purpura: Mechanisms of pathogenesis. Oncologist 2009;14:12-21.
13. Kurien BT, Hensley K, Bachmann M, Scofield RH. Oxidatively modified autoantigens in autoimmune diseases. Free Radic Biol Med 2006;41:549-556.
14. Kurien BT, Scofield RH. Autoimmunity and oxidatively modified autoantigens. Autoimmun Rev 2008;7:567-573.
15. Chou MY, Fogelstrand L, Hartvigsen K, Hansen LF, Woelkers D, Shaw PX, Choi J, Perkmann T, Backhed F, Miller YI, Horkko S, Corr M, Witztum JL, Binder CJ. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest 2009;119:1335-1349.
16. Kannan S. Free radical theory of autoimmunity. Theor Biol Med Model 2006;3:22.
17. Finkelstein E, Rosen GM, Rauckman EJ. Spin trapping of superoxide and hydroxyl radical: Practical aspects. Arch Biochem Biophys 1980;200:1-16.
18. Griffiths HR. Is the generation of neo-antigenic determinants by free radicals central to the development of autoimmune rheumatoid disease? Autoimmun Rev 2008 7 544-549.
19. Kamata H, Hirata H. Redox regulation of cellular signalling. Cell Signal 1999;11:1-14.
20. Ohno Y, Kanoh T, Uchino H. Idiopathic thrombocytopenic purpura with defective oxidative metabolism of neutrophils. Nippon Ketsueki Gakkai Zasshi 1984;47:1257-1264.
21. Polat G, Tamer L, Tanriverdi K, Gurkan E, Baslamisli F, Atik U. Levels of malondialdehyde, glutathione and ascorbic acid in idiopathic thrombocytopaenic purpura. East Afr Med J 2002;79:446-449.
22. Akbayram S, Dogan M, Akgun C, Mukul Y, Peker E, Bay A, Caksen H, Oner AF. The association of oxidant status and antioxidant capacity in children with acute and chronic itp. J Pediatr Hematol Oncol 2010;32:277-281.
23. Zhang B, Lo C, Shen L, Sood R, Jones C, Cusmano-Ozog K, Park-Snyder S, Wong W, Jeng M, Cowan T, Engleman EG, Zehnder J. The role of vanin-1 and oxidative stress-related pathways in distinguishing acute and chronic pediatric itp. Blood 2011.
24. Neunert C, Lim W, Crowther M, Cohen A, Solberg Jr L, Crowther MA. The American society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190-4207.
25. Begonja AJ, Teichmann L, Geiger J, Gambaryan S, Walter U. Platelet regulation by NO/cGMP signaling and NAD(P)H oxidase-generated ROS. Blood Cells Mol Dis 2006;36:166-170.
26. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura. Current concepts in pathophysiology and management. Thromb Haemost 2008;99:4-13.
27. Iuchi Y, Kibe N, Tsunoda S, Suzuki S, Mikami T, Okada F, Uchida K, Fujii J. Implication of oxidative stress as a cause of autoimmune hemolytic anemia in NZB mice. Free Radic Biol Med 2010;48:935-944.
28. Sanner BM, Meder U, Zidek W, Tepel M. Effects of glucocorticoids on generation of reactive oxygen species in platelets. Steroids 2002;67:715-719.
29. Morganti RP, Cardoso MH, Pereira FG, Lorand-Metze I, De Nucci G, Marcondes S, Antunes E. Mechanisms underlying the inhibitory effects of lipopolysaccharide on human platelet adhesion. Platelets 2010;21:260-269.
30. Sill JC, Proper JA, Johnson ME, Uhl CB, Katusic ZS. Reactive oxygen species and human platelet GP IIb/IIIa receptor activation. Platelets 2007;18:613-619.
31. Nardi MA, Gor Y, Feinmark SJ, Xu F, Karpatkin S. Platelet particle formation by anti GPIIIa49-66 Ab, Ca2u ionophore A23187, and phorbol myristate acetate is induced by reactive oxygen species and inhibited by dexamethasone blockade of platelet phospholipase a2, 12-lipoxygenase, and NADPH oxidase. Blood 2007;110:1989-1996.
32. Tiede MP, Ahn ER, Jy W, Scagnelli T, Bidot CJ, Horstman LL, Jimenez JJ, Ahn YS. Life-threatening hypercoagulable state following splenectomy in ITP: Successful management with aggressive antithrombotic therapy and danazol. Clin Appl Thromb Hemost 2005;11:347-352.
33. Krotz F, Sohn HY, Pohl U, Reactive oxygen species. Players in the platelet game. Arterioscler Thromb Vasc Biol 2004;24:1988-1996.
34. Olas B, Wachowicz B. Role of reactive nitrogen species in blood platelet functions. Platelets 2007;18:555-565.
35. Wolin MS, Gupte SA, Oeckler RA. Superoxide in the vascular system. J Vasc Res 2002;39:191-207.
36. Filomeni G, Ciriolo MR. Redox control of apoptosis: An update. Antioxid Redox Signal 2006;8:2187-2192.
37. Cerella C, Coppola S, Maresca V, De Nicola M, Radogna F, Ghibelli L. Multiple mechanisms for hydrogen peroxideinduced apoptosis. Ann N Y Acad Sci 2009;1171:559-563.
38. Chen Q, Chai YC, Mazumder S, Jiang C, Macklis RM, Chisolm GM, Almasan A. The late increase in intracellular free radical oxygen species during apoptosis is associated with cytochrome C release, caspase activation, and mitochondrial dysfunction. Cell Death Differ 2003;10:323-334.
39. Stefanescu R, Bassett D, Modarresi R, Santiago F, Fakruddin M, Laurence J. Synergistic interactions between interferon-gamma and trail modulate c-FLIP in endothelial cells, mediating their lineage-specific sensitivity to thrombotic thrombocytopenic purpura plasma-associated apoptosis. Blood 2008;112:340-349.
40. Houwerzijl EJ, Blom NR, van der Want JJ, Esselink MT, Koornstra JJ, Smit JW, Louwes H, Vellenga E, de Wolf JT. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004;103:500-506.
41. Houwerzijl EJ, Blom NR, van der Want JJ, Vellenga E, de Wolf JT. Megakaryocytic dysfunction in myelodysplastic syndromes and idiopathic thrombocytopenic purpura is in part due to different forms of cell death. Leukemia 2006;20:1937-1942.
42. Berchtold P, Wenger M. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: Their clinical significance and response to treatment. Blood 1993;81:1246-1250.
43. Hayes JD, Pulford DJ. The glutathione s-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995;30:445-600.
44. Marwick JA, Ito K, Adcock IM, Kirkham PA. Oxidative stress and steroid resistance in asthma and copd: Pharmacological manipulation of HDAC-2 as a therapeutic strategy. Expert Opin Ther Targets 2007;11:745-755.
45. Maiti AK. Gene network analysis of oxidative stress-mediated drug sensitivity in resistant ovarian carcinoma cells. Pharmacogenomics J 2010;10:94-104.
46. Memisogullari R, Taysi S, Bakan E, Capoglu I. Antioxidant status and lipid peroxidation in type II diabetes mellitus. Cell Biochem Funct 2003;21:291-296.
47. Cimbaljevic B, Vasilijevic A, Cimbaljevic S, Buzadzic B, Korac A, Petrovic V, Jankovic A, Korac B. Interrelationship of antioxidative status, lipid peroxidation, and lipid profile in insulin-dependent and non-insulin-dependent diabetic patients. Can J Physiol Pharmacol 2007;85:997-1003.
48. Zhang Q, Ye DQ, Chen GP, Zheng Y. Oxidative protein damage and antioxidant status in systemic lupus erythematosus. Clin Exp Dermatol 2010;35:287-294.
49. Kalpakcioglu B, Senel K. The interrelation of glutathione reductase, catalase, glutathione peroxidase, superoxide dismutase, and glucose-6-phosphate in the pathogenesis of rheumatoid arthritis. Clin Rheumatol 2008;27:141-145.
50. Thachil J. Nitric oxide in immune thrombocytopenic purpura. Hematology 2009;14:59-62.
51. Wachowicz B, Rywaniak JZ, Nowak P. Apoptotic markers in human blood platelets treated with peroxynitrite. Platelets 2008;19:624-635.
52. Salama A. Current treatment options for primary immune thrombocytopenia. Expert Rev Hematol 2011;4:107-118.
53. Pignatelli P, Di Santo S, Buchetti B, Sanguigni V, Brunelli A, Violi F. Polyphenols enhance platelet nitric oxide by inhibiting protein kinase c-dependent NADPH oxidase activation: Effect on platelet recruitment. FASEB J 2006;20:1082-1089.
54. Chakrabarti S, Clutton P, Varghese S, Cox D, Mascelli MA, Freedman JE. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release. Thromb Res 2004;113:225-233.
55. Vitseva O, Varghese S, Chakrabarti S, Folts JD, Freedman JE. Grape seed and skin extracts inhibit platelet function and release of reactive oxygen intermediates. J Cardiovasc Pharmacol 2005;46:445-451.
56. Pignatelli P, Sanguigni V, Paola SG, Lo Coco E, Lenti L, Violi F. Vitamin C inhibits platelet expression of CD40 ligand. Free Radic Biol Med 2005;38:1662-1666.
57. Kuwana M, Nomura S, Fujimura K, Nagasawa T, Muto Y, Kurata Y, Tanaka S, Ikeda Y. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 2004;103:1229-1236.